Literature DB >> 21822797

Perspectives on the role of mTORC2 in B lymphocyte development, immunity and tumorigenesis.

Adam S Lazorchak1, Bing Su.   

Abstract

Mammalian target of rapamycin complex 2 (mTORC2) is a key downstream mediator of phosphoinositol-3-kinase (PI3K) dependent growth factor signaling. In lymphocytes, mTORC2 has emerged as an important regulator of cell development, homeostasis and immune responses. However, our current understanding of mTORC2 functions and the molecular mechanisms regulating mTORC2 signaling in B and T cells are still largely incomplete. Recent studies have begun to shed light on this important pathway. We have previously reported that mTORC2 mediates growth factor dependent phosphorylation of Akt and facilitates Akt dependent phosphorylation and inactivation of transcription factors FoxO1 and FoxO3a. We have recently explored the functions of mTORC2 in B cells and show that mTORC2 plays a key role in regulating survival and immunoglobulin (Ig) gene recombination of bone marrow B cells through an Akt2-FoxO1 dependent mechanism. Ig recombination is suppressed in proliferating B cells to ensure that DNA double strand breaks are not generated in actively dividing cells. Our results raise the possibility that genetic or pharmacologic inhibition of mTORC2 may promote B cell tumor development as a result of inefficient suppression of Ig recombination in dividing B cells. We also propose a novel strategy to treat cancers based on our recent discovery that mTORC2 regulates Akt protein stability.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21822797      PMCID: PMC4875240          DOI: 10.1007/s13238-011-1077-3

Source DB:  PubMed          Journal:  Protein Cell        ISSN: 1674-800X            Impact factor:   14.870


  54 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

Review 2.  Regulating antigen-receptor gene assembly.

Authors:  Mark S Schlissel
Journal:  Nat Rev Immunol       Date:  2003-11       Impact factor: 53.106

Review 3.  Accessibility and the developmental regulation of V(D)J recombination.

Authors:  M S Schlissel; P Stanhope-Baker
Journal:  Semin Immunol       Date:  1997-06       Impact factor: 11.130

4.  Foxo1 regulates marginal zone B-cell development.

Authors:  Jing Chen; Jose J Limon; Caroline Blanc; Stanford L Peng; David A Fruman
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

5.  Sin1-mTORC2 suppresses rag and il7r gene expression through Akt2 in B cells.

Authors:  Adam S Lazorchak; Dou Liu; Valeria Facchinetti; Annarita Di Lorenzo; William C Sessa; David G Schatz; Bing Su
Journal:  Mol Cell       Date:  2010-08-13       Impact factor: 17.970

6.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

7.  Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells.

Authors:  Michael G Kharas; Jonathan A Deane; Stephane Wong; Karen R O'Bosky; Naomi Rosenberg; Owen N Witte; David A Fruman
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

8.  PI3 kinase signals BCR-dependent mature B cell survival.

Authors:  Lakshmi Srinivasan; Yoshiteru Sasaki; Dinis Pedro Calado; Baochun Zhang; Ji Hye Paik; Ronald A DePinho; Jeffrey L Kutok; John F Kearney; Kevin L Otipoby; Klaus Rajewsky
Journal:  Cell       Date:  2009-10-30       Impact factor: 41.582

9.  Down-regulation of RAG1 and RAG2 gene expression in preB cells after functional immunoglobulin heavy chain rearrangement.

Authors:  U Grawunder; T M Leu; D G Schatz; A Werner; A G Rolink; F Melchers; T H Winkler
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

10.  BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism.

Authors:  Alina Patke; Ingrid Mecklenbräuker; Hediye Erdjument-Bromage; Paul Tempst; Alexander Tarakhovsky
Journal:  J Exp Med       Date:  2006-10-23       Impact factor: 14.307

View more
  4 in total

1.  An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.

Authors:  Kameswaran Ravichandran; Iram Zafar; Zhibin He; R Brian Doctor; Radu Moldovan; Adam E Mullick; Charles L Edelstein
Journal:  Hum Mol Genet       Date:  2014-05-08       Impact factor: 6.150

2.  NGF signaling in PC12 cells: the cooperation of p75(NTR) with TrkA is needed for the activation of both mTORC2 and the PI3K signalling cascade.

Authors:  Sara Negrini; Rosalba D'Alessandro; Jacopo Meldolesi
Journal:  Biol Open       Date:  2013-07-12       Impact factor: 2.422

Review 3.  Targeting mTOR in Acute Lymphoblastic Leukemia.

Authors:  Carolina Simioni; Alberto M Martelli; Giorgio Zauli; Elisabetta Melloni; Luca M Neri
Journal:  Cells       Date:  2019-02-21       Impact factor: 6.600

Review 4.  The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses.

Authors:  Ghada A Soliman
Journal:  Nutrients       Date:  2013-06-19       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.